NCT05576272 2023-11-22
A Phase II/III Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Nasopharyngeal Carcinoma
Qilu Pharmaceutical Co., Ltd.
Phase 2/3 Unknown
Clinical Trials
9 trialsNCT04221516 2023-06-18
Camrelizumab After Completion of Radiotherapy for Oligometastatic Nasopharyngeal Carcinoma
Nanfang Hospital, Southern Medical University
Phase 2 Unknown
NCT04586088 2023-05-06
Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure
Sun Yat-sen University
Phase 2 Unknown
NCT05724355 2023-02-13
CDK4/6 Inhibitor Plus Camrelizumab for PD-1 Inhibitor Refractory R/M NPC
Sun Yat-sen University
Phase 2 Unknown
NCT05549466 2023-02-08
Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R/M NPC
Sun Yat-sen University
Phase 2 Unknown
NCT04978012 2022-06-07
Fluzoparib and Camrelizumab in Treating Patients With R/M NPC That Progressed After First-line Chemotherapy
Fudan University
Phase 2 Unknown
NCT04143984 2022-04-29
Carbon-Ion Radiotherapy Plus Camrelizumab for Locally Recurrent Nasopharyngeal Carcinoma
Shanghai Proton and Heavy Ion Center
Phase 2 Unknown
NCT04547088 2020-09-14
Camrelizumab Combined With Apatinib in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2 Unknown
NCT04548271 2020-09-14
Camrelizumab Combined With Apatinib in Patients With PD-1 Antagonists Resistant Recurrent/Metastatic Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2 Unknown